Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVL006 + sacituzumab tirumotecan
- Development stage
- Unknown
- Lead developer
- Convalife Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CVL006 + sacituzumab tirumotecan is a combination therapy under early clinical investigation for advanced solid tumors. **CVL006** is a novel bispecific antibody that targets both **programmed death-ligand 1 (PD-L1)** and **vascular endothelial growth factor (VEGF)**, functioning through immune checkpoint inhibition and angiogenesis blockade. It is created by fusing an anti-PD-L1 VHH domain with a humanized anti-VEGF IgG1, and retains antibody-dependent cellular cytotoxicity (ADCC) functionality. **Sacituzumab tirumotecan** (DS-8201a) is an antibody-drug conjugate (ADC), consisting of a monoclonal antibody targeting human trophoblast cell-surface antigen 2 (Trop-2) linked to the topoisomerase I inhibitor deruxtecan. Together, the combination is being studied for enhanced antitumor efficacy via dual immune checkpoint blockade, anti-angiogenesis, and targeted cytotoxicity in solid tumors[1][2][3][4].
- Brand names
- DS-8201aDS8201aDS 8201a
- Other names
- SKB264SKB-264SKB 264CVL006 + DS-8201aCVL006 + sacituzumab tirumotecan
02
Targets
TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on CVL006 + sacituzumab tirumotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVL006 + sacituzumab tirumotecan.